CRISPR Therapeutics vs Travere Therapeutics

CRISPR Therapeutics (CRSP), health care, and Travere Therapeutics (TVTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Travere Therapeutics is worth $4.9B on the stock market and CRISPR Therapeutics $3.9B: Travere Therapeutics is valued at 26% more. CRISPR Therapeutics's operating margin in its latest fiscal year was -18934% and Travere Therapeutics's -12.8%. Over the past year CRISPR Therapeutics's share price has moved -24.5% and Travere Therapeutics's +38.1%.

Key facts

CRISPR Therapeutics market value
$3.9B
Travere Therapeutics market value
$4.9B
CRISPR Therapeutics revenue
$3.5MFY to 2025-12-31
Travere Therapeutics revenue
$490.7MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

CRISPR Therapeutics vs Travere Therapeutics: every measure side by side
Measure CRISPR Therapeutics Travere Therapeutics
SectorHealth CareHealth Care
Country Switzerland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$3.9Blower$4.9Bhigher
Revenue$3.5Mlower$490.7Mhigher
Earnings-$581.6Mlower-$25.5Mhigher
Employees—497
Total assets$2.3Bhigher$605.2Mlower
Valuation
P/E——
P/S1110higher10.0lower
P/B—217
Dividend yield—0.00%
Profitability
Operating margin-18934%lower-12.8%higher
Balance sheet
Net assets$1.9Bhigher$114.8Mlower
Total liabilities$343.4Mlower$490.4Mhigher
Total debt——
Cash on hand$347.6Mhigher$93Mlower
Price change
Today-0.54%lower+2.82%higher
1 year-24.5%lower+38.1%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

CRISPR Therapeutics only (1)

Travere Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns CRSP · Who owns TVTX

Further comparisons

Learn

Questions and answers

Which is bigger, CRISPR Therapeutics or Travere Therapeutics?

By market value, Travere Therapeutics is the larger: $4.9B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, Travere Therapeutics is the larger: $490.7M against $3.5M for CRISPR Therapeutics.

Which has the higher operating margin?

Travere Therapeutics: -12.8%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both CRISPR Therapeutics and Travere Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds CRISPR Therapeutics and 1 holds Travere Therapeutics.

Cite this page

Funkfolio, “CRISPR Therapeutics vs Travere Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/crsp-vs-tvtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.